IDH1 and glioblastoma: A review of the current available literature suggests that GTR increases the likelihood of 1- and 2-year survival.31 Recent evidence also suggests that complete resection of the T1 contrast-enhancing portion in addition to a portion of the surrounding T2 hyperintensity is associated with a survival benefit over resection of the T1 contrast-enhancing portion alone in glioblastoma and that maximizing EOR may confer an additional survival advantage in patients with tumors harboring certain mutant genes including IDH1.